Is Eledon Pharmaceuticals, Inc. (ELDN) a Buy, Sell, or Hold?
NASDAQ : ELDN
Eledon Pharmaceuticals, Inc.
$4.07 USD
$0.23 (5.99%)
- Volume
- 783.05K
- Average Volume
- 1.45M
- Market Capitalization
- $243.99M
- P/E Ratio
- -4.68
- Dividend Yield
- 0.00%
- Price Target
- $5.00
- Year High
- $4.60
- Year Low
- $1.35
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.44
Company Overview
NASDAQ
David-Alexandre C. Gros
Biotechnology
Healthcare
ELDN
33
US
USD
Liquidity Metrics
0.01
8.44
8.44
0.46
0.00
Sales & Valuation
-$
0.00
4.55
-3.54
-0.61
Profitability
-$0.56
-$45.62M
0.00%
0.00%
-96.80%
-53.28%
P/E Metrics
-4.68
0.00
0.00
Analyst Price Target & Rating
$5.00
$5.00
$5.00
2/5
4 Analysts
-18.60%
Poll Results
About Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Stock
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, Calif ... ornia.
2026-06-25 07:00:00
AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera's Prospera kidney transplant assessment test into Eledon's planned Phase 3 clinical trial of tegoprubart, an in.
2026-06-22 14:12:08
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation Transcript
2026-06-22 07:00:00
Eledon Presents Long-Term Phase 2 BESTOW Results at ATC Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?
2026-06-16 10:41:03
Here is how Eledon Pharmaceuticals, Inc. (ELDN) and Galderma Group AG - Unsponsored ADR (GALDY) have performed compared to their sector so far this year.
2026-06-08 07:00:00
– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no longer requiring exogenous insulin therapy to manage their T1D – All 12 patients also achieved an HbA1c below 6.5%, with a mean most recent HbA1c of approximately 5.4%, representing an approximately 2.6% average improvement in HbA1c from baseline – No severe hypoglycemic episodes were reported post-transplant, compared with a history of recurrent severe hypoglycemic events prior to transplantation in all enrolled patients IRVINE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced updated results from an investigator-initiated trial evaluating tegoprubart, its investigational anti-CD40L antibody, as part of a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes undergoing allogeneic islet cell transplantation at the University of Chicago Medicine Transplant Institute.
2026-06-04 16:31:28
IRVINE, Calif. , June 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant Institute will be presented by Piotr Witkowski, M. D. , Ph.
2026-06-04 16:31:00
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at ADA
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?
2026-05-29 10:40:50
Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.
Frequently Asked Questions
-
What is the current Eledon Pharmaceuticals, Inc. (ELDN) stock price?
-
Eledon Pharmaceuticals, Inc.(NASDAQ:ELDN) stock price is $4.07 in the last trading session. During the trading session, ELDN stock reached the peak price of $4.6 while $1.35 was the lowest point it dropped to. The percentage change in ELDN stock occurred in the recent session was 5.99% while the dollar amount for the price change in ELDN stock was $0.23.
-
ELDN's industry and sector of operation?
-
The NASDAQ listed ELDN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ELDN?
-
Bryan E. Smith | General Counsel, Corporate Secretary & Chief Compliance Officer
John Herberger | Vice President of Technical Operations
Paul Sean Little | Chief Financial Officer
Marina Escudero | Vice President & Head of Clinical Operations
David Hovland | Chief Regulatory Officer -
How many employees does ELDN have?
-
Number of ELDN employees currently stands at 33. ELDN operates from 19900 MacArthur Boulevard, Irvine, CA 92612, US.
-
Link for ELDN official website?
-
Official Website of ELDN is: https://eledon.com
-
How do I contact ELDN?
-
ELDN could be contacted at phone #949 238 8090 and can also be accessed through its website. ELDN operates from 19900 MacArthur Boulevard, Irvine, CA 92612, US.
-
How many shares of ELDN are traded daily?
-
The average number of ELDN shares traded daily for last 3 months was 1.45M.
-
What is the market cap of ELDN currently?
-
The market value of ELDN currently stands at $243.99M with its latest stock price at $4.07